As Progress Software (PRGS) Shares Declined, University Of Notre Dame Du Lac Raised Holding by $1.05 Million; Celgene (CELG) Market Value Declined While Birchview Capital LP Has Decreased by $1.77 Million Its Stake

May 26, 2018 - By Dolores Ford

Progress Software Corporation (NASDAQ:PRGS) Logo

Birchview Capital Lp decreased its stake in Celgene Corp (CELG) by 2.23% based on its latest 2017Q4 regulatory filing with the SEC. Birchview Capital Lp sold 17,000 shares as the company’s stock declined 19.30% with the market. The institutional investor held 744,051 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $77.65 million, down from 761,051 at the end of the previous reported quarter. Birchview Capital Lp who had been investing in Celgene Corp for a number of months, seems to be less bullish one the $57.11 billion market cap company. The stock decreased 1.14% or $0.91 during the last trading session, reaching $78.63. About 4.78 million shares traded. Celgene Corporation (NASDAQ:CELG) has declined 31.28% since May 26, 2017 and is downtrending. It has underperformed by 42.83% the S&P500.

University Of Notre Dame Du Lac increased its stake in Progress Software Corp (PRGS) by 17.13% based on its latest 2017Q4 regulatory filing with the SEC. University Of Notre Dame Du Lac bought 25,031 shares as the company’s stock declined 9.58% with the market. The institutional investor held 171,187 shares of the prepackaged software company at the end of 2017Q4, valued at $7.29 million, up from 146,156 at the end of the previous reported quarter. University Of Notre Dame Du Lac who had been investing in Progress Software Corp for a number of months, seems to be bullish on the $1.69B market cap company. The stock decreased 1.83% or $0.69 during the last trading session, reaching $37.09. About 215,467 shares traded. Progress Software Corporation (NASDAQ:PRGS) has risen 36.89% since May 26, 2017 and is uptrending. It has outperformed by 25.34% the S&P500.

Since April 19, 2018, it had 0 insider purchases, and 1 insider sale for $492,819 activity.

More news for Progress Software Corporation (NASDAQ:PRGS) were recently published by: Businesswire.com, which released: “Progress Enables Developers to Quickly Add Chatbots to Apps Using the Industry’s Leading UI Tools – Telerik and …” on May 08, 2018. Businesswire.com‘s article titled: “Progress Reveals Three Latest Progress Labs Innovation Projects” and published on May 22, 2018 is yet another important article.

Investors sentiment decreased to 0.95 in Q4 2017. Its down 0.19, from 1.14 in 2017Q3. It is negative, as 26 investors sold PRGS shares while 71 reduced holdings. 31 funds opened positions while 61 raised stakes. 41.24 million shares or 4.96% less from 43.39 million shares in 2017Q3 were reported. The Nebraska-based Ameritas Investment Prtn has invested 0.01% in Progress Software Corporation (NASDAQ:PRGS). 8,362 are held by Landscape Capital Mgmt. Chicago Equity Ptnrs Ltd Liability Co has invested 0.31% in Progress Software Corporation (NASDAQ:PRGS). Barclays Public Limited Com accumulated 71,596 shares. 14,850 were accumulated by Bridgecreek Invest Mngmt Limited Liability Co. Public Employees Retirement Association Of Colorado holds 9,557 shares or 0% of its portfolio. 23,595 were accumulated by Cornercap Invest Counsel. 7,266 are held by Parallax Volatility Advisers L P. Gsa Capital Partners Llp holds 0.17% of its portfolio in Progress Software Corporation (NASDAQ:PRGS) for 64,945 shares. Proshare Advisors Ltd Liability Corporation holds 0% or 8,526 shares in its portfolio. Bnp Paribas Arbitrage Sa holds 0.01% in Progress Software Corporation (NASDAQ:PRGS) or 72,023 shares. Brinker Capital Inc accumulated 5,997 shares. Vident Inv Advisory Ltd Company holds 0.03% of its portfolio in Progress Software Corporation (NASDAQ:PRGS) for 15,803 shares. Parkside National Bank & Trust reported 34 shares stake. American Gru Incorporated has invested 0.01% of its portfolio in Progress Software Corporation (NASDAQ:PRGS).

Among 3 analysts covering Progress Software Corporation (NASDAQ:PRGS), 0 have Buy rating, 1 Sell and 2 Hold. Therefore 0 are positive. Progress Software Corporation had 14 analyst reports since October 2, 2015 according to SRatingsIntel. The firm has “Hold” rating by Wedbush given on Thursday, March 29. The firm has “Neutral” rating given on Friday, October 2 by Wedbush. Wedbush maintained the stock with “Neutral” rating in Friday, June 24 report. The stock of Progress Software Corporation (NASDAQ:PRGS) earned “Buy” rating by Benchmark on Tuesday, January 2. The company was maintained on Thursday, January 11 by Benchmark. Benchmark maintained Progress Software Corporation (NASDAQ:PRGS) rating on Friday, January 15. Benchmark has “Buy” rating and $31.0 target. The stock has “Neutral” rating by Wedbush on Wednesday, January 18. The firm earned “Sell” rating on Thursday, March 8 by Benchmark. The stock of Progress Software Corporation (NASDAQ:PRGS) earned “Buy” rating by Benchmark on Monday, January 18. The firm has “Buy” rating given on Wednesday, January 18 by Benchmark.

University Of Notre Dame Du Lac, which manages about $481.90M US Long portfolio, decreased its stake in Seattle Genetics Inc (NASDAQ:SGEN) by 9,535 shares to 45,784 shares, valued at $2.45M in 2017Q4, according to the filing. It also reduced its holding in Insmed Inc (NASDAQ:INSM) by 115,292 shares in the quarter, leaving it with 87,121 shares, and cut its stake in Alnylam Pharmaceuticals Inc (NASDAQ:ALNY).

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on July, 26. They expect $1.87 EPS, up 11.31% or $0.19 from last year’s $1.68 per share. CELG’s profit will be $1.36B for 10.51 P/E if the $1.87 EPS becomes a reality. After $1.61 actual EPS reported by Celgene Corporation for the previous quarter, Wall Street now forecasts 16.15% EPS growth.

Among 35 analysts covering Celgene Corporation (NASDAQ:CELG), 20 have Buy rating, 1 Sell and 14 Hold. Therefore 57% are positive. Celgene Corporation had 149 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Friday, June 23. The stock has “Buy” rating by UBS on Friday, November 6. The firm earned “Equal-Weight” rating on Friday, October 20 by Barclays Capital. Morgan Stanley maintained it with “Underweight” rating and $115 target in Monday, October 23 report. The stock of Celgene Corporation (NASDAQ:CELG) earned “Neutral” rating by Citigroup on Friday, October 27. The firm earned “Buy” rating on Wednesday, February 28 by Stifel Nicolaus. The stock has “Buy” rating by SunTrust on Thursday, January 7. The company was maintained on Friday, October 20 by Stifel Nicolaus. Morgan Stanley maintained it with “Equal-Weight” rating and $93 target in Friday, April 13 report. The stock of Celgene Corporation (NASDAQ:CELG) earned “Outperform” rating by Credit Suisse on Tuesday, April 19.

Since February 8, 2018, it had 2 insider buys, and 3 selling transactions for $3.48 million activity. 3,260 shares valued at $299,594 were bought by Alles Mark J on Thursday, February 8. LOUGHLIN JAMES J sold $851,093 worth of stock or 9,250 shares. MARIO ERNEST sold $1.26 million worth of Celgene Corporation (NASDAQ:CELG) on Friday, February 23.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Seekingalpha.com which released: “Will ‘Public Shaming’ Sink Celgene?” on May 21, 2018, also Seekingalpha.com with their article: “Celgene: Still (Looks) Appealing” published on May 21, 2018, Seekingalpha.com published: “My 2 Cents On The Ozanimod Saga” on May 15, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Finance.Yahoo.com and their article: “Celgene Corporation: How to Effectively Buy Into CELG Stock” published on May 22, 2018 as well as 247Wallst.com‘s news article titled: “Short Interest Remains Mixed in Major Biotechs” with publication date: May 25, 2018.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: